Accurate Wealth Management LLC Sells 27,611 Shares of Boston Scientific Corporation $BSX

Key Points

• Accurate Wealth Management LLC sold 27,611 shares of Boston Scientific Corporation, decreasing its stake by 90.5%, leaving it with only 2,901 shares valued at approximately $301,000.
• Boston Scientific reported earnings per share (EPS) of $0.75 for the last quarter, surpassing estimates of $0.72, with revenue of $5.06 billion, exceeding expectations of $4.89 billion.
• Analysts have raised their price targets for Boston Scientific, with Robert W. Baird boosting it to $123.00 and Raymond James to $124.00, indicating a generally bullish sentiment towards the stock.

Accurate Wealth Management LLC lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 90.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,901 shares of the medical equipment provider's stock after selling 27,611 shares during the quarter. Accurate Wealth Management LLC's holdings in Boston Scientific were worth $301,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. HM Payson & Co. increased its position in Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after acquiring an additional 98 shares during the last quarter. Park Square Financial Group LLC lifted its stake in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the period. HHM Wealth Advisors LLC boosted its holdings in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after buying an additional 103 shares during the last quarter. Rise Advisors LLC raised its position in Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock worth $85,000 after acquiring an additional 103 shares during the period. Finally, Forum Financial Management LP grew its position in shares of Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after acquiring an additional 112 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Boston Scientific stock opened at $98.03 on Friday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm's fifty day moving average is $103.90 and its 200 day moving average is $102.06. The company has a market cap of $145.26 billion, a price-to-earnings ratio of 58.35, a PEG ratio of 2.36 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent research reports. Robert W. Baird boosted their price target on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial raised their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Truist Financial raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and a consensus target price of $118.17.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 over the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.